Alvotech (NASDAQ:ALVO) Announces Quarterly Earnings Results, Misses Expectations By $0.19 EPS

Alvotech (NASDAQ:ALVO) announced its quarterly earnings data on Wednesday. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.19), Zacks reports.

Alvotech Trading Up 0.8%

NASDAQ ALVO traded up $0.04 during trading hours on Wednesday, reaching $4.92. The company’s stock had a trading volume of 779,973 shares, compared to its average volume of 765,719. The business has a 50-day simple moving average of $5.28 and a 200 day simple moving average of $4.21. Alvotech has a 52 week low of $2.94 and a 52 week high of $6.53. The stock has a market cap of $1.48 billion, a PE ratio of -8.07 and a beta of 0.24.

Latest Alvotech News

Here’s some of the latest news about ALVO:

• Positive Sentiment: Third-quarter product and service revenue rose 78% year over year to $58.2 million, while adjusted EBITDA more than doubled to $31.5 million. The FDA also accepted Alvotech’s application for its proposed Entyvio biosimilar, and approved Simlandi manufacturing changes that more than double output per batch. Alvotech financial results and business update
• Neutral Sentiment: Alvotech maintained 2026 revenue guidance of $650 million–$700 million and EBITDA guidance of $180 million–$220 million. The revenue range is broadly in line with the $652.5 million consensus estimate, though management expects results toward the lower end.
• Negative Sentiment: Nine-month adjusted revenue declined 23% year over year to $323.4 million, and gross margin contracted to 54% from 59%. Cash fell to $61.5 million from $172.4 million at year-end 2025; operating cash outflow was $205.6 million, adding to liquidity concerns. Alvotech financial results and business update

Wall Street Analysts Forecast Growth

ALVO has been the topic of a number of research analyst reports. Jefferies Financial Group started coverage on Alvotech in a report on Tuesday. They set a “buy” rating and a $9.00 target price on the stock. Wall Street Zen lowered Alvotech from a “hold” rating to a “sell” rating in a research report on Saturday. UBS Group set a $8.00 price objective on Alvotech in a research note on Wednesday, September 16th. Weiss Ratings upgraded Alvotech from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, November 4th. Finally, Zacks Research downgraded shares of Alvotech from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. Five research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $8.40.

Alvotech Company Profile

Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.